Posts by Vijaya Ramesh, PhD
-
Proteasome Inhibitors Have Therapeutic Potential for Tumors Associated with Neurofibromatosis Type 2
Srirupa Bhattacharyya, PhD, Vijaya Ramesh, PhD, and colleagues present cell and animal evidence that targeting the ubiquitin proteasome pathway, particularly with ixazomib, is a potential approach to the treatment of meningiomas and schwannomas associated with neurofibromatosis type 2.
-
Novel Pharmacotherapeutic Approach Identified for NF2-Deficient Nervous System Tumors
Roberta L. Beauchamp and Vijaya Ramesh, PhD, of the Center for Genomic Medicine, and colleagues believe co-targeting the mTOR and IGF1R/IR pathways will be a compelling strategy for treating tumors characterized by loss of the neurofibromatosis 2 tumor suppressor gene.
Biography
Dr. Ramesh is a Professor of Neurology at Harvard Medical School and an Associate Neurologist at MGH. She obtained her PhD from University of Madras, India and completed postdoctoral training in the laboratories of James Gusella (MGH) and Dr. Vivian Shih (MGH). The Ramesh laboratory works on NF2 and TSC, employing disease-relevant human cellular models to discover pathways and mechanisms of pathophysiology and using the results to identify single and combination drug treatment, which could be translated into the clinic.
